Paion AG (PAIOF PINK) stock market data APIs
$0.02
0(0%)
as of January 13, 2025
Paion AG Financial Data Overview
Price chart is built with
Anychart
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
Prev. Close
0.02
Open
0.02
Volume
0
High
0.02
Low
0.02
52 wk Range
0.02-0.07
Market Cap
151 K
Shares Outstanding
7 526 K
Revenue
14 808 K
EPS
-0.1045
Beta
1.611
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Paion AG data using free add-ons & libraries
Get Paion AG Fundamental Data
Paion AG Fundamental data includes:
- Net Revenue: 14 808 K
- EBITDA: -15 836 169
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-22
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Paion AG News
New
Paion Third Quarter 2022 Earnings: €0.10 loss per share (vs €0.09 loss in 3Q 2021)
Paion (ETR:PA8) Third Quarter 2022 Results Key Financial Results Revenue: €371.0k (down 80% from 3Q 2021). Net loss: €6.99m (loss widened by 14% from 3Q 2021). €0.10 loss per share (further de...
We're Not Worried About Paion's (ETR:PA8) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mone...
At UK£3.10, Is Essentra plc (LON:ESNT) Worth Looking At Closely?
While Essentra plc (LON:ESNT) might not be the most widely known stock at the moment, it saw a double-digit share price rise of over 10% in the past couple of months on the LSE. Less-covered, small ca...
At UK£3.10, Is Essentra plc (LON:ESNT) Worth Looking At Closely?
While Essentra plc (LON:ESNT) might not be the most widely known stock at the moment, it saw a double-digit share price rise of over 10% in the past couple of months on the LSE. Less-covered, small ca...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
